Impact of Screening Mammography on Treatment in Women Diagnosed with Breast Cancer

Abstract

Background

Screening mammography reduces breast cancer mortality; however, screening recommendations, ordering, and compliance remain suboptimal and controversies regarding the value of screening persist. We evaluated the influence of screening mammography on the extent of breast cancer treatment.

Methods

Patients ≥ 40 years of age diagnosed with breast cancer from September 2008 to May 2016 at a single institution were divided into two groups: those with screening 1–24 months prior to diagnosis, and those with screening at 25+ months, including patients with no prior mammography. The association between the two groups and various clinical factors were assessed using logistic regression models. Subgroup analysis was performed based on age groups.

Results

Analysis included 1125 patients, 819 (73%) with screening at 1–24 months, and 306 (27%) with screening at 25+ months, including 65 (6%) who never had mammography. Overall, patients in the 25+ months group were more likely to receive chemotherapy [odds ratio (OR) 1.51, p = 0.0040], undergo mastectomy (OR 1.32, p = 0.0465), and require axillary dissection (AD; OR 1.66, p = 0.0045) than those in 1–24 months group. On subgroup analysis, patients aged 40–49 years with no prior mammography were more likely to have larger tumors (p = 0.0323) and positive nodes (OR 4.52, p = 0.0058), undergo mastectomy (OR 3.44, p = 0.0068), undergo AD (OR 4.64, p = 0.0002), and require chemotherapy (OR 2.52, p = 0.0287) than the 1–24 months group.

Conclusions

Screening mammography is associated with decreased stage at diagnosis and receipt of less-extensive treatment. This was evident in all groups, including the 40–49 years age group, where controversy exists on whether screening is even necessary.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Shapiro S. Periodic screening for breast cancer: the HIP randomized controlled trial. JNCI Monogr. 1997;22:27–30.

    Article  Google Scholar 

  2. 2.

    Tabár L, Fagerberg CJG, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. The Lancet. 1985;325(8433):829–32.

    Article  Google Scholar 

  3. 3.

    Tabár L, Vitak B, Chen TH-H, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260:658–63.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. The Lancet. 1999;353:1903–8.

    CAS  Article  Google Scholar 

  5. 5.

    Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1-breast cancer detection and death rates among women aged 40–49 years. Can Med Assoc J. 1992;147:1459–76.

    CAS  Google Scholar 

  6. 6.

    Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. 1988;297:943.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Frisell J, Lidbrink E, Hellstrom L, Rutqvist LE. Follow-up after 11 years: update of mortality results in the Stockholm mammographic screening trial Breast Cancer. Res Treat. 1997;45:263–70.

    CAS  Article  Google Scholar 

  8. 8.

    Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer. 1997;80:2091–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States, 2016: with chartbook on long-term trends in health. 2017. https://www.cdc.gov/nchs/data/hus/hus16.pdf. Accessed 17 Mar 2018.

  10. 10.

    National Comprehensive Cancer Network (NCCN) Guidelines. NCCN clinical practice guidelines in oncology. Breast cancer screening and diagnosis. 2017. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. Accessed 17 Mar 2018.

  11. 11.

    Monticciolo DL, Newell MS, Hendrick RE, et al. Breast cancer screening for average-risk women: recommendations from the ACR commission on breast imaging. J Am Coll Radiol. 2017;14(9):1137–43.

    Article  Google Scholar 

  12. 12.

    United States Preventive Services Task Force. Breast cancer: screening recommendations. 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening. Accessed 17 Mar 2018.

  13. 13.

    Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk 2015 guideline update from the American Cancer Society. JAMA. 2015;314(15):1599–614.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    American Cancer Society Cancer. Cancer treatment and survivorship facts and figures 2014–2015. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2014-2015.pdf. Accessed 17 Mar 2018.

  16. 16.

    American Cancer Society. Breast cancer facts and figures 2017–2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf. Accessed 17 Mar 2018.

  17. 17.

    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–92.

    CAS  Article  Google Scholar 

  18. 18.

    Saadatmand S, Bretveld R, Siesling S, et al. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ. 2015;351:h4901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,826 breast cancer survivors. Breast Cancer Res and Treat. 2007;106(3):439–51.

    Article  Google Scholar 

  20. 20.

    Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008;14(6):429–34.

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Collichio F, Pandya K. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival. Oncology. 1994;8(12):45–52.

    CAS  PubMed  Google Scholar 

  22. 22.

    Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol. 2006;18(1):24–8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Support Palliat Care. 2007;1(1):57–62.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Kummerow KL, Du L, Penson DF, et al. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150(1):9–16.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Garcia-Etienne CA, Tomatis M, Joerg Heil, et al. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer. 2012;48(13):1947–56.

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213–9.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Harris JR, Murphy PH, McNeese M, Mendelhall NP, Morrow M, Robert NJ. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–90.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    National Comprehensive Cancer Network (NCCN) guidelines. NCCN clinical practice guidelines in oncology. Invasive breast cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 20 Apr 2018.

  31. 31.

    Truong PT, Olivotto IA, Whelan TJ, et al. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ. 2004;170:1263–73.

    Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Ann Surg Oncol. 2017;24(1):38–51.

    Article  Google Scholar 

  33. 33.

    Hinrichs CS, Watroba NL, Rezaishiraz H, et al. Lymphedema secondary to postmastectomy radiation: incidence and risk factors. Ann Surg Oncol. 2004;11(6):573–80.

    Article  Google Scholar 

  34. 34.

    Sparano JA, Gray JR, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018. https://doi.org/10.1056/nejmoa1804710.

    Article  PubMed  Google Scholar 

  35. 35.

    Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Int Med. 2016;164(4):244–55.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Elisa Port MD, FACS.

Ethics declarations

Disclosure

Authors have no financial disclosures.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ahn, S., Wooster, M., Valente, C. et al. Impact of Screening Mammography on Treatment in Women Diagnosed with Breast Cancer. Ann Surg Oncol 25, 2979–2986 (2018). https://doi.org/10.1245/s10434-018-6646-8

Download citation

Keywords

  • Breast Cancer
  • Screening Mammography
  • Prior Mammography
  • United States Preventive Services Task Force (USPSTF)
  • Screening Interval